Form 4: MacroGenics Chief Medical Officer Stephen L. Eck Reports Stock Transactions

Stephen L. Eck, Chief Medical Officer of MacroGenics Inc., reports the vesting and disposal of restricted stock units and common stock transactions on February 15, 2025.

Summary

• On February 19, 2025, Stephen L. Eck, the Chief Medical Officer of MacroGenics Inc. (MGNX), filed a Form 4 with the SEC.
• The report details transactions that occurred on February 15, 2025, involving common stock and restricted stock units (RSUs).
• Specifically, 16,665 restricted stock units vested and converted into common stock.
• Eck disposed of 4,942 shares of common stock at a price of $2.56 per share to cover tax obligations.
• Following these transactions, Eck directly owns 29,377 shares of MacroGenics common stock and 16,665 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine filing of stock transactions by a company insider, and doesn't inherently indicate positive or negative sentiment.

Future Outlook

The reporting person will have 33% of the 50,000 restricted stock units granted on February 15, 2023 vest each year thereafter.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to the market.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect insider activity related to compensation.

Key Dates